Shearman & Sterling represented Citigroup, BofA Securities, Goldman Sachs & Co. LLC, and Mizuho as joint book-running managers and representatives of the underwriters in connection with Amgen’s registered $24 billion notes offering, consisting of $2 billion 5.250% Senior Notes due 2025, $1.5 billion 5.507% Senior Notes due 2026, $3.75 billion 5.150% Senior Notes due 2028, $2.75 billion 5.250% Senior Notes due 2030, $4.25 billion 5.250% Senior Notes due 2033, $2.75 billion 5.600% Senior Notes due 2043, $4.25 billion 5.650% Senior Notes due 2053 and $2.75 billion 5.750% Senior Notes due 2063.

Amgen is a global biotechnology company that discovers, develops, manufactures and delivers human therapeutics based on advances in cellular and molecular biology.

The Team